# Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

> **NCT05050084** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NRG Oncology** · enrollment: 2050 (estimated)

## Conditions studied

- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Bicalutamide
- **DRUG:** Buserelin
- **DRUG:** Darolutamide
- **DRUG:** Degarelix
- **DRUG:** Flutamide
- **DRUG:** Goserelin
- **DRUG:** Histrelin
- **DRUG:** Leuprolide
- **RADIATION:** Radiation Therapy
- **DRUG:** Relugolix
- **DRUG:** Triptorelin

## Key facts

- **NCT ID:** NCT05050084
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-06
- **Primary completion:** 2026-11-11
- **Final completion:** 2026-11-11
- **Target enrollment:** 2050 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050084, "Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05050084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*